Boehringer Ingelheim Vetmedica has launched Benefortin (benazepril hydrochloride), an ACE inhibitor licensed for the treatment of congestive heart failure (CHF) in dogs. It is also licensed for the treatment of chronic renal insufficiency (CRI) in cats.

Benefortin uses novel micro-cap technology to mask the taste of the bitter molecule. According to Boehringer, this ensures that Benefortin tastes good¹, even if it is bitten, crunched or chewed. The company says taste tests demonstrated 100% palatability in dogs and 92% palatability in cats in home settings¹.

Benefortin is available in 5mg and 20mg tablets for dogs and 2.5mg tablets for cats and dogs.

Jemima Scott, Boehringer Ingelheim brand manager said: "The addition of Benefortin to our cardiology portfolio now enables us to provide veterinary practices with two of the cornerstones of canine CHF treatment, and the palatability of Benefortin makes it an excellent choice for vets needing to prescribe an ACE inhibitor." 

To support the launch of Benefortin, Boehringer is offering veterinary practices the opportunity to win one of three Bosch microwave ovens in a prize draw by answering three multiple choice questions on the ACE inhibitor.

For further information on Benefortin, contact your local Boehringer Ingelheim Vetmedica territory manager or telephone 01344 746959.

PS: Whilst you're here, take a moment to see our latest job opportunities for vet nurses.